NEOGENOMICS INC — Director's Dealing 2020

Mar 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2020-03-01

Reporting Person: SHOVLIN ROBERT J. (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-01	Common Stock	F	810	—	Disposed	144830	Direct
2020-03-02	Common Stock	A	8736	—	Acquired	153566	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-02	Common Stock	$28.33	A	56271	Acquired	2027-03-02	Common Stock (56271.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (66667.0)	66667	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (192334.0)	192334	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (66897.0)	66897	Direct

Footnotes

F1: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock.

F2: On April 28, 2017, Mr. Shovlin was granted 200,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date.